JAN 23, 2018 6:06 AM PST

Enhancing Dendritic Cells to Fight Cancer

WRITTEN BY: Kara Marker

Scientists propose extracting dendritic cells and priming them to fight cancer before returning them to a patient as part of a new immunotherapy approach. From the Ecole Polytechnique Fédérale de Lausanne (EPFL), researchers are looking to maximize current cancer immunotherapy methods to be powerful and very accurate.

Two images of EVIR-engineered dendritic cells (green) capturing tumor antigens in exosomes (gold/red). Cell nuclei are colored blue. Credit: M. De Palma/EPFL

A vital part of the immune system, dendritic cells are antigen-presenting cells, which means they identify, bind, and bring proteins unique to foreign invaders to show killer T cells. As their name suggests, killer T cells are the ones who destroy tumor cells.

“Dendritic cells acquire immunogenic antigens from the tumor and directly display them on their own surface," explained Michele De Palma.

The new technique focuses on improving the way dendritic cells recognize tumor antigens. Researchers extract dendritic cells from a cancer patient, which are exposed to tumor antigens and injected back into the patient. In theory, this process prepares dendritic cells so they are more equipped to find and present antigens in the patient so killer T cells can destroy the tumor. In the past, scientists have had trouble with tumor cells (and their antigens) evading detection by the immune system.

This approach isn’t perfect. The antigens exposed to dendritic cells after their extraction from the cancer patient are not identical to the antigens the dendritic cells actually come into contact with in the body. This variance increases the risk of killer T cells not being properly activated to kill tumor cells.

In the new study published in Nature Methods, EPFL researchers offer a solution: extracellular vesicle-internalizing receptors (EVIR). These are artificial receptors that help dendritic cells “selectively and efficiently” identify and bind tumor antigens in the body to present to killer T cells.

Scientists inject EVIRs into the dendritic cell, where they recognize exosomal proteins. These are small vesicles within the cell that, in the context of cancer, are released by tumors and are rich with tumor antigens. In past studies, exosomal proteins have been associated with promoting metastasis, the spreading of a tumor to various tissues.

EVIRs essentially introduce tumor antigens from exosomes to dendritic cells so they can better target them. Palma says that this is an “unconventional route for antigen presentation to T cells."

"The EVIR technology can intercept a natural phenomenon - the release of exosomes from tumors - to the patient's benefit," explained first author Mario Leonardo Squadrito. "It exploits pro-tumoral exosomes as selective nanocarriers of tumor antigens, making them available to the immune system for cancer recognition and rejection."

Scientists from the study plan on investigating the relationship between EVIRs, dendritic cells, antigens, and exosomal proteins further. Additionally studies will have to be done before the new immunotherapy approach can be applied as a cancer treatment.

Source: Ecole Polytechnique Fédérale de Lausanne

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAR 16, 2020
Drug Discovery & Development
MAR 16, 2020
Critical Interleukin Leads to Drug Discovery
The immune molecule interleukin-2 (IL-2) is a growth factor that stimulates the immune system to produce T-cells. Their ...
MAR 29, 2020
Cell & Molecular Biology
MAR 29, 2020
Learning More About Boosting Immunity in Older Adults
Older adults are more susceptible to infections and don't generate a robust immune response after a vaccination.
APR 22, 2020
Drug Discovery & Development
APR 22, 2020
Only 3% of COVID-19 Antibody Tests Approved by FDA
So far, only 3% of at least 90 COVID-19 antibody tests in the US have been approved by the Food and Drug Administration ...
APR 10, 2020
Drug Discovery & Development
APR 10, 2020
Cancer Therapy Drug Reverses Kidney Damage
According to a study published in the journal Science Translational Medicine, a therapeutic previously used for cancer t ...
MAY 21, 2020
Drug Discovery & Development
MAY 21, 2020
Molecular 'Switch' Makes Autoimmune Drugs Fight Cancer
Researchers from the Antibody and Vaccine Group at the University of Southampton, England, have identified a way to repu ...
MAY 26, 2020
Immunology
MAY 26, 2020
The Hunt for Rare Immune Cells, to InfinityFlow and Beyond
The immune landscape is staggeringly complex, with a myriad of genetically and functionally distinct immune cell subpopu ...
Loading Comments...